Journey Medical Corp(DERM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,838 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
DERM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Journey Medical Corp (DERM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DERM at 16.5/100 on a 32-signal composite quality model, placing it at rank #2,838 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (4.7) and earnings quality (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Journey Medical Corp reports quarterly revenue of $18.5M, net income of $-312.0K. Top institutional holders of DERM by reported 13-F value include WASATCH ADVISORS, TANG CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. DERM trades on the Nasdaq exchange and files with the SEC under CIK 1867066. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DERM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Journey Medical Corp directly from SEC EDGAR. Journey Medical Corp's 13F Pro composite quality score has ranged between 16 and 34 since 2024, currently 16.5 — a stable long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$18.5M
Net Income
Q2 2026
$-312.0K
ROIC
Q2 2026
2.9%
D/E Ratio
Q2 2026
0.95
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+10.2% YoYNet Income
+22.1% YoYOperating Income
+40.3% YoYEPS (Diluted)
+34.7% YoYTotal Assets
+17.9% YoYTotal Debt
+1.6% YoYOp. Cash Flow
-36.3% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $61.9M +10.2% | $56.1M -29.1% | $79.2M +7.5% | $73.7M +16.7% | $63.1M +41.8% | $44.5M |
| Net Income | $-11.4M +22.1% | $-14.7M -280.8% | $-3.9M +87.0% | $-29.6M +32.7% | $-44.0M -932.7% | $5.3M |
| Operating Income | $-8.2M +40.3% | $-13.7M -559.8% | $-2.1M +92.5% | $-27.5M +21.1% | $-34.9M -544.3% | $7.9M |
| EPS (Diluted) | $-0.47 +34.7% | $-0.72 -242.9% | $-0.21 +87.6% | $-1.69 +60.9% | $-4.32 -981.6% | $0.49 |
| Total Assets | $94.6M +17.9% | $80.2M +4.4% | $76.8M -26.9% | $105.2M +8.1% | $97.3M +87.4% | $51.9M |
| Total Debt | $25.3M +1.6% | $24.9M +70.1% | $14.6M -47.3% | $27.8M | — | — |
| Operating Cash Flow | $-12.4M -36.3% | $-9.1M -274.2% | $5.2M +138.7% | $-13.5M -520.5% | $-2.2M -142.5% | $5.1M |
| Free Cash Flow | — | $-24.1M -10152.9% | $240.0K +100.7% | $-33.5M | — | — |
Get alerted when DERM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Journey Medical Corp including:
Top Institutional Holders of DERM
WASATCH ADVISORS LP
$20.2M2,858,930 shTANG CAPITAL MANAGEMENT LLC
$11.4M1,610,000 shVANGUARD CAPITAL MANAGEMENT LLC
$4.8M675,185 shPUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$3.8M536,000 shPale Fire Capital SE
$3.7M528,584 shOpaleye Management Inc.
$2.5M350,000 shSummit Financial, LLC
$2.5M346,748 shJANE STREET GROUP, LLC
$2.3M320,021 shDiametric Capital, LP
$2.1M295,663 shIkarian Capital, LLC
$1.8M251,436 sh
| Fund | Value | Shares |
|---|---|---|
| WASATCH ADVISORS LP | $20.2M | 2,858,930 |
| TANG CAPITAL MANAGEMENT LLC | $11.4M | 1,610,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.8M | 675,185 |
| PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. | $3.8M | 536,000 |
| Pale Fire Capital SE | $3.7M | 528,584 |
| Opaleye Management Inc. | $2.5M | 350,000 |
| Summit Financial, LLC | $2.5M | 346,748 |
| JANE STREET GROUP, LLC | $2.3M | 320,021 |
| Diametric Capital, LP | $2.1M | 295,663 |
| Ikarian Capital, LLC | $1.8M | 251,436 |
Companies Similar to DERM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pelthos Therapeutics Inc.
HERON THERAPEUTICS, INC. /DE/
ORTHOPEDIATRICS CORP
CUMBERLAND PHARMACEUTICALS INC
UroGen Pharma Ltd.
DELCATH SYSTEMS, INC.
HARROW, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put DERM on your watchlist
Track score changes the day Journey Medical Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DERM a good stock to buy?
13F Pro's AI-powered analysis of Journey Medical Corp (DERM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DERM are available on the DERM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DERM is classified as a small company.
Which hedge funds own DERM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DERM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Journey Medical Corp's investment landscape.